PACS Group, Inc. (PACS)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$50.26+7.67%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
Research Workspace
Put PACS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 11% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 28% in its worst 12-month stretch.
View RiskPACS's skilled nursing operations have to keep compounding to justify the price. Revenue grew 11.5% year over year in the latest quarter. The company raised its full-year revenue guidance to $5.95 billion to $6.05 billion. It trades at 22 times earnings versus a 26 times peer median. The price reflects less growth than we forecast. A guidance cut after a recent raise would be a severe credibility hit. Peer multiples imply a price about 8% below where it trades. Our read remains intact. This read is provisional.
Trailing returns as of 2026-11-04. PACS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering PACS (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare PACS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PACS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Compare the value case
Put PACS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase Adjusted EBITDA guidance for 2026
Directly confirms raised EBITDA and revenue guidance objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase Adjusted EBITDA guidance for 2026
Earnings beat and raised guidance directly confirm growth objectives.
CEO stock sale raises concerns about leadership stability.
Advances: Expand footprint through strategic acquisitions
Expansion plans and acquisitions align with growth objectives.
Advances: Reaffirm and increase revenue guidance for 2026
Raising revenue guidance positively impacts growth expectations.
Advances: Reaffirm and increase revenue guidance for 2026
Earnings call confirms increased revenue guidance for 2026.
Advances: Increase Adjusted EBITDA guidance for 2026
Earnings beat supports increased Adjusted EBITDA guidance.
Advances: Reaffirm revenue guidance for 2026
Price target increase reflects confidence in revenue guidance.